about
Fluconazole Resistance Patterns in Candida Species that Colonize Women with HIV InfectionMicrobiological, epidemiological, and clinical characteristics and outcomes of patients with cryptococcosis in Taiwan, 1997-2010How I treat mucormycosis.Epidemiological characterization and prognostic factors in patients with confirmed cerebral cryptococcosis in central Taiwan.Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.Antifungal activity of tamoxifen: in vitro and in vivo activities and mechanistic characterizationAntifungal drug resistance mechanisms.Strategies to manage antifungal drug resistance.Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.In Vivo Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis.Breakthrough invasive fungal diseases during voriconazole treatment for aspergillosis: A 5-year retrospective cohort study.Endophytic fungal compounds active against Cryptococcus neoformans and C. gattii.Chemosensitization as a means to augment commercial antifungal agents.Structural optimization of berberine as a synergist to restore antifungal activity of fluconazole against drug-resistant Candida albicans.A high-throughput assay of yeast cell lysis for drug discovery and genetic analysis.[Identification of fungal pathogens in tissue samples using fluorescence in situ hybridization].In vivo imaging of disseminated murine Candida albicans infection reveals unexpected host sites of fungal persistence during antifungal therapy.Diagnosis and management of a fatal case of sepsis caused by Candida parapsilosis sensu stricto in a neonate with omphalocele.Current role of echinocandins in the management of invasive aspergillosis.Assessing responses to treatment of opportunistic mycoses and salvage strategies.ChromoblastomycosisPersistent Candidemia: Causes and Investigations
P2860
Q34404892-A35E3746-9147-4EE8-9077-CA7722D312B2Q34685419-1E951582-96B9-4293-9CE5-DEF1EB63F0BCQ35797637-2360B80B-F8E8-4609-82EC-235FDEA56580Q35806654-FDA4FF0B-CF94-4BE2-935B-B998BA015035Q37164085-13116F2D-A5A1-40F9-9499-9044257D4411Q37274621-11E39E6D-3D58-4ABB-BE0E-BC887CDF88B0Q37463223-AB44BFAB-CFDB-4B55-8C8D-EBD045950832Q37827872-796CB39E-B5EB-422F-9CF5-6E5DCA250F1CQ38880522-3C095739-947A-4973-84F7-3E51116C10AFQ40248126-B48DD953-7B87-4171-A8CD-E6EAC4502323Q40562624-376A2923-C64E-4B88-A703-B31FE4760501Q41355547-977A4FDB-C4CD-4D4C-9D09-6D2E9DC28851Q42141903-2F782AEC-E53E-4343-B13E-91685818F511Q42707707-B4E7BCC5-51A8-4A18-B29C-90A0040741E6Q43030507-DA16156D-6F7B-48C7-81C4-78124CE996BEQ43445390-A55E329A-68B6-4823-98E0-3D8AAC58F892Q44264237-822C7EAD-3BA9-4C64-9DA8-9D7B8406B9D9Q48514102-38991BC0-EC54-4F1D-A143-08C8260D9C57Q53217028-3EF6307C-0CFD-4EE7-AAB0-61A42E140D58Q54346621-A7C3070F-B1B2-401A-AC38-FB71E39EDFB7Q56915677-B172B3D8-C973-4441-B2D1-41ED0D97A413Q56970743-2A3C7294-2D41-4468-829F-7236C044D049
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
When primary antifungal therapy fails.
@en
When primary antifungal therapy fails.
@nl
type
label
When primary antifungal therapy fails.
@en
When primary antifungal therapy fails.
@nl
prefLabel
When primary antifungal therapy fails.
@en
When primary antifungal therapy fails.
@nl
P2860
P356
P1476
When primary antifungal therapy fails.
@en
P2860
P304
P356
10.1086/587101
P407
P577
2008-05-01T00:00:00Z